Abstract
Precision treatment with targeted cancer drugs requires the selection of patients who are most likely to benefit from a given therapy. We argue here that the use of a combination of both DNA and transcriptome analyses will significantly improve drug response prediction.
©2016 American Association for Cancer Research.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Molecular Targeted Therapy
-
Mutation*
-
Neoplasms / drug therapy*
-
Neoplasms / genetics*
-
Patient Selection
-
Precision Medicine
-
Sequence Analysis, DNA
-
Sequence Analysis, RNA
-
Treatment Outcome